VNTN yields 2000000.00% · ABBV yields 3.06%● Live data
📍 VNTN pulled ahead of the other in Year 1
Combined, VNTN + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VNTN + ABBV for your $10,000?
VentureNet Capital Group, Inc. provides capital and media marketing services to public companies. It offers custom-tailored and structured products, such as PIPE financing, stock loans, equity lines of credit, and asset based financing, as well as purchases aged debt from public companies. The company's media marketing services include arrangement of investor meetings, lunches/dinners; preparation and distributions of Company reports; positioning of company for review/analysis by the sell-side, buy-side and individual investor audience; and featuring company to two exclusive, high net-worth individual investor groups, as well as conducts audio-taped CEO Webcast/audio press releases, radio interviews on the wall street news hour, and other financial radio programs. Its media marketing services also arrange for company to be included in financial newsletters and publications sent to brokers, investors, and investment bankers monthly, as well as features company on financial Websites. In addition, the company offers reverse mergers services, which consist of preparation of S-1 registration statements and form 10 filings; and handling of legal work, filings, market makers to file form 211, access to capital, and institutional and retail support for stocks. VentureNet Capital Group, Inc. was incorporated in 1989 and is based in Reno, Nevada.
Full VNTN Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.